By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ChromaDex, Inc. 

10005 Muirlands Boulevard
Suite G, First Floor
Irvine  California  92618  U.S.A.
Phone: 949-419-0288 Fax: 949-419-0294


SEARCH JOBS


Industry
Biotechnology






Company News
ChromaDex, Inc. Release: U.S. FDA Issues GRAS No Objection Letter For NIAGEN 8/16/2016 12:20:06 PM
ChromaDex, Inc. Vindicated By Retraction And Apology From Author Of Misleading And Factually Inaccurate Article 6/30/2016 1:49:43 PM
ChromaDex, Inc. Added To The Russell 2000 Index 6/28/2016 11:41:21 AM
ChromaDex, Inc. Release: University Researchers Show Vitamin Nicotinamide Riboside Is An Effective Tool For Managing The Negative Effects Of Obesity And Diabetes 6/1/2016 8:16:21 AM
ChromaDex, Inc. Announces Reverse Stock Split As Company Seeks To List Its Common Stock On The NASDAQ Capital Market 4/13/2016 8:11:14 AM
ChromaDex, Inc. Announces Commencement Of An Obesity-Related Clinical Study Of NIAGEN In Collaboration With The University of Copenhagen And Aarhus University 2/22/2016 11:50:11 AM
A Letter From the ChromaDex, Inc. Chief Executive Officer 1/6/2016 8:53:38 AM
ChromaDex, Inc. To Present At 27th Annual Piper Jaffray Healthcare Conference 11/24/2015 10:37:30 AM
Jarrow Formulas Plans U.S. Retail Launch Of A Nicotinamide Riboside Product Featuring ChromaDex, Inc.’s NIAGEN 11/23/2015 10:16:32 AM
NIH And ChromaDex, Inc. Announce Material Cooperative Research And Development Agreement To Study The Effects Of Chromadex’s NIAGEN Nicotinamide Riboside On Cockayne Syndrome And Ataxia Telangiectasia 11/18/2015 7:21:41 AM
12345678910...
//-->